Showing 161 - 180 results of 18,834 for search '(( 50 a decrease ) OR ((( 40 nm decrease ) OR ( 50 ((ng decrease) OR (we decrease)) ))))', query time: 0.56s Refine Results
  1. 161
  2. 162
  3. 163
  4. 164
  5. 165
  6. 166

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  7. 167

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  8. 168

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  9. 169

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  10. 170

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  11. 171
  12. 172
  13. 173

    Transforming Small-Molecule Nanoaggregation into Functional Drug Delivery Platforms by JunHyuk Kim (21235657)

    Published 2025
    “…The IC<sub>50</sub> value of <b>Nano-CC1-Acl</b> further decreases to 0.20 ± 0.16 μM in the presence of cysteine, a biothiol. …”
  14. 174

    Transforming Small-Molecule Nanoaggregation into Functional Drug Delivery Platforms by JunHyuk Kim (21235657)

    Published 2025
    “…The IC<sub>50</sub> value of <b>Nano-CC1-Acl</b> further decreases to 0.20 ± 0.16 μM in the presence of cysteine, a biothiol. …”
  15. 175
  16. 176
  17. 177
  18. 178
  19. 179
  20. 180